Immune System News and Research

RSS

Researchers identify a new way to prolong the circulation of cancer-fighting nanoparticles in the bloodstream

For a number of innovative and life-saving medical treatments, from organ replacements and skin grafts to cancer therapy and surgery, success often depends on slipping past or fending off the body's immune system.

24 Oct 2018

Study uncovers rare phenomenon of antibodies working together against malaria

Scientists investigating how the human immune system defends against malaria have uncovered a rare phenomenon: antibodies working together to bind to a vulnerable spot on the parasite.

24 Oct 2018

Scientists develop nanodevice to deliver immunotherapy without side effects

Houston Methodist scientists have developed a nanodevice to deliver immunotherapy without side effects to treat triple-negative breast cancer.

24 Oct 2018

Map of human liver cells reveals molecular make-up of individual cells

A map of the cells in the human liver has been created by University Health Network Transplant Program and University of Toronto researchers, revealing for the first time differences between individual cells at the molecular level which can have a profound impact on their behaviour in tissue, tumours and disease.

From 10x Genomics, Inc. 23 Oct 2018

New discovery may lead to better treatment options for pancreatic cancer patients

Pancreatic cancer is one of the most difficult cancers to treat and is a leading cause of cancer-related deaths. Now, Sidney Kimmel Cancer Center - Jefferson Health and Lankenau Institute for Medical Research scientists find that a gene involved in the immune system called IDO2 plays a significant role in pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer.

23 Oct 2018

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.

23 Oct 2018

New approach may lead to better diagnostic techniques for autoimmune disorders

If we really want to know how our body's cells work - or don't work, in the case of disease - we might need to look beyond their genes and even beyond the proteins they are made of.

23 Oct 2018

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.

23 Oct 2018

Innovative strategy opens up new avenue of treatment for anthrax infections

A team led by Professor Arne Skerra at the Technical University of Munich has developed an innovative strategy for preventing the anthrax bacterium from absorbing iron, which is crucial for its survival.

22 Oct 2018

Drug cocktail that increases lifespan discovered

A team of researchers led by Principal Investigator Dr Jan Gruber from Yale-NUS College has discovered a combination of pharmaceutical drugs that not only increases healthy lifespan in the microscopic worm Caenorhabditis elegans (C. elegans), but also delays the rate of ageing in them, a finding that could someday mean longer, healthier lives for humans.

22 Oct 2018

Researchers discover how acne-causing bacteria resist treatment

Researchers in Sweden have discovered how acne-causing bacteria feed off their human hosts. The study, which was performed at KTH Royal Institute of Technology, could make it possible to find effective ways to treat severe acne.

22 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Researchers produce artificial antibody capable of blocking prions in the laboratory

Prion diseases affect the brain, causing neurodegenerative problems that always lead to death. They attracted attention in the late 1990s due to the "Mad Cow" scare.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

A high concentration of multi-strain probiotic helps to reduce mild to moderate episodes of chemotherapy-induced diarrhea in cancer patients, according to results of a phase II/III study in India.

22 Oct 2018

Immunotherapy trial offers new hope for people with aggressive breast cancer

There is new hope for people with an aggressive type of breast cancer, as an immunotherapy trial shows for the first time that lives can be extended in people with triple-negative breast cancer.

22 Oct 2018

Immune System News and Research

Researchers identify a new way to prolong the circulation of cancer-fighting nanoparticles in the bloodstream

Study uncovers rare phenomenon of antibodies working together against malaria

Scientists develop nanodevice to deliver immunotherapy without side effects

Map of human liver cells reveals molecular make-up of individual cells

New discovery may lead to better treatment options for pancreatic cancer patients

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

New approach may lead to better diagnostic techniques for autoimmune disorders

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

Innovative strategy opens up new avenue of treatment for anthrax infections

Drug cocktail that increases lifespan discovered

Researchers discover how acne-causing bacteria resist treatment

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Researchers produce artificial antibody capable of blocking prions in the laboratory

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Immunotherapy trial offers new hope for people with aggressive breast cancer

Immunology eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News